Table VI.
Rank analysis of PASI 90 response rate of the drugs for treating psoriasis.
| Treatment | Rank 1 | Rank 2 | Rank 3 | Rank 4 | Rank 5 | Rank 6 | Rank 7 | Rank 8 | Rank 9 | Rank 10 | Rank 11 | Rank 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | 0.01 | 0.03 | 0.05 | 0.13 | 0.21 | 0.28 | 0.22 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 |
| Briakinumab | 0.86 | 0.08 | 0.03 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CSA 5 mg | 0.03 | 0.07 | 0.04 | 0.06 | 0.07 | 0.09 | 0.14 | 0.25 | 0.17 | 0.05 | 0.01 | 0.00 |
| Etanercept 25 mg BIW | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.23 | 0.59 | 0.14 | 0.00 | 0.00 |
| Etanercept 25 mg QW | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.81 | 0.07 |
| Etanercept 50 mg BIW | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 | 0.18 | 0.35 | 0.35 | 0.01 | 0.00 | 0.00 | 0.00 |
| Infliximab 3 mg | 0.02 | 0.04 | 0.09 | 0.09 | 0.22 | 0.24 | 0.20 | 0.09 | 0.02 | 0.00 | 0.00 | 0.00 |
| Infliximab 5 mg | 0.05 | 0.23 | 0.16 | 0.30 | 0.18 | 0.08 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| MTX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.18 | 0.70 | 0.10 | 0.00 |
| Placebo | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.93 |
| Ustekinumab 45 mg | 0.01 | 0.18 | 0.35 | 0.21 | 0.14 | 0.08 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ustekinumab 90 mg | 0.02 | 0.37 | 0.28 | 0.16 | 0.10 | 0.05 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Rank 1 indicates the best rating, while Rank 12 indicates the worst rating. PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.